Review

hnRNP A1: The Swiss Army Knife of Gene Expression

Jacques Jean-Philippe, Sean Paz and Massimo Caputi *

Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Rd, Boca Raton, FL 33431, USA; E-Mails: jjeanph3@fau.edu (J.J.-P.); cprsean@gmail.com (S.P.)

* Author to whom correspondence should be addressed; E-Mail: mcaputi@fau.edu;
Tel.: +1-561-297-0627; Fax: +1-561-297-2221.

Received: 12 August 2013; in revised form: 2 September 2013 / Accepted: 4 September 2013 / Published: 16 September 2013

Abstract: Eukaryotic cells express a large variety of RNA binding proteins (RBPs), with diverse affinities and specificities towards target RNAs. These proteins play a crucial role in almost every aspect of RNA biogenesis, expression and function. The heterogeneous nuclear ribonucleoproteins (hnRNPs) are a complex and diverse family of RNA binding proteins. hnRNPs display multiple functions in the processing of heterogeneous nuclear RNAs into mature messenger RNAs. hnRNP A1 is one of the most abundant and ubiquitously expressed members of this protein family. hnRNP A1 plays multiple roles in gene expression by regulating major steps in the processing of nascent RNA transcripts. The transcription, splicing, stability, export through nuclear pores and translation of cellular and viral transcripts are all mechanisms modulated by this protein. The diverse functions played by hnRNP A1 are not limited to mRNA biogenesis, but extend to the processing of microRNAs, telomere maintenance and the regulation of transcription factor activity. Genomic approaches have recently uncovered the extent of hnRNP A1 roles in the development and differentiation of living organisms. The aim of this review is to highlight recent developments in the study of this protein and to describe its functions in cellular and viral gene expression and its role in human pathologies.

Keywords: hnRNP; mRNA; transcription; splicing; translation; telomere; miRNA
1. Introduction

In the past decade, advances in genomic research have highlighted the fundamental role that post-transcriptional events play in the regulation of gene expression. RNA binding proteins (RBPs) control and regulate the various steps of the maturation of nascent transcripts. RBPs modulate the capping, splicing, polyadenylation, nuclear export, stability rates and translation of cellular messenger RNAs (mRNAs) by binding specific sequences or secondary structures within the transcripts. Heterogeneous nuclear ribonucleoproteins (hnRNPs) are among the best-studied and largest families of RBPs.

Historically, hnRNPs have been defined as proteins that associate with nascent transcripts (namely, pre-mRNAs or hnRNAs), precursors of the functional, protein coding mRNAs [1]. Initial studies indicated that nascent RNA polymerase II (RNAPII) transcripts were packaged with six “core” hnRNP proteins (A1, A2, B1, B2, C1 and C2) in a bead on a string structure that resembles the organization of DNA nucleosomes [2]. However, the biochemical and functional characterization of over 20 individual hnRNPs, with distinct RNA binding specificities, led to a complex model characterized by dynamic hnRNP complexes, regulating the processing and expression of the nascent transcripts.

The hnRNP family is composed of at least 20 abundant, major hnRNPs and other less abundant, minor members. The more abundant family members, named A through U, have molecular weights ranging from 34 kDa to 120 kDa [1,3]. hnRNPs share a modular structure consisting of one or more RNA-binding domains (RBDs). RNA recognition motifs (RRMs) are the most common RBDs found in hnRNPs; these globular domains are highly conserved and are found in several other protein families. RRM s are approximately 90 amino acids-long and have the capacity to participate in both general and specific interactions with nucleic acids [4]. Other common RBDs that contribute to the binding specificity of the single hnRNPs are: RGG boxes, which are repeats of Arg-Gly-Gly with interspersed aromatic amino acids and K-homology (KH) domains, characterized by evolutionarily conserved sequence of around 70 amino acids [5,6]. In addition to RBDs, hnRNPs contain auxiliary domains, such as glycine-rich, acidic or proline-rich domains, which mediate protein-protein interactions, subcellular localization and the functional specificity of single proteins [7]. Biochemical and bioinformatics approaches have shown that hnRNPs play both a constitutive role, as RNA packaging proteins, in RNA biogenesis, and a regulatory role by binding specific RNA sequences and by interacting with other regulatory factors; such functions are dependent on both RBDs and auxiliary domains. hnRNPs undergo several post-translational modifications, including phosphorylation, SUMOylation, ubiquitination and methylation, which regulate their activities. Although hnRNPs generally have a diffuse nuclear distribution, many remain bound to the mRNA as it is transported through nuclear pores, associates with the ribosome or is sequestered in specific cellular compartments. Hence, post-translational modifications may modulate hnRNPs activity by altering their localization, RNA binding specificity and interaction with other cellular factors [8].

The complex formed by hnRNPs and nascent transcripts is highly dynamic, and it is remodeled through the loss or acquisition of hnRNPs and other proteins. The interaction of hnRNPs, as well as other RNA-binding proteins with a given transcript creates what has been termed the “mRNP code” [9], which regulates the maturation and expression of eukaryotic genes. Variation in the relative amount or modification in the activity of hnRNPs leads to changes in the processing, localization, stability and translation of the transcripts. Immunohistochemical data and a vast array of
gene expression studies [10] revealed that hnRNPs are ubiquitously expressed in all tissue types to varying abundance levels, and their relative stoichiometry, across cell types, is not fixed. This suggests a role for this protein family as master regulators of gene expression. More recently, genome-wide analysis of cellular transcripts provided evidence of the combinatorial role of hnRNPs on global cellular gene expression, the regulation of cellular differentiation and the response to physiological stimuli [11].

Our understanding of the functions of single hnRNPs is highly uneven. Few hnRNPs have been widely studied, while little information is available about the structure and function of the rest. The following sections will review our current understanding of hnRNP A1, a member of the A/B subfamily and arguably the best known among the hnRNPs. We will highlight the multifunctional nature of this protein, describing its role in several cellular processes.

2. The hnRNP A/B Family

hnRNP A1 is a member of the hnRNP A/B subfamily, which comprises four paralogues, A1, A2/B1, A3 and A0, and two more distantly related proteins, B2 and AB [12,13]. Initial studies indicated that members of the hnRNP A/B and hnRNP C subfamilies package nascent transcripts in a non-sequence-specific manner, constituting the core hnRNP particle [2,14]. Subsequent analysis of hnRNPs A/B binding specificities have shown that these proteins have also distinct and specific preferences for a specific subset of RNA sequences [15–18]. The molecular basis of the duality in the RNA-binding ability of the hnRNP A/B family members is not well understood. It is conceivable that both the multiple RNA binding domains present within hnRNPs A/B and the local concentration of these proteins within specific subcellular compartments might contribute to both general scaffolding and sequence-specific RNA binding activities. The hnRNPs A/B sequence-specific binding activity and their ability to interact with other cellular factors allow for a multiplicity of functions in pre-mRNA splicing, mRNA trafficking, translation, microRNA (miRNA) processing and telomerase maintenance.

3. Structural Features of hnRNP A1

hnRNP A1 is one of the most abundant nuclear proteins, rivaling histones in its amount, and although multiple alternatively spliced transcript variants have been predicted for this gene, only two transcripts have been validated experimentally: A1-B, the full-length isoform of 372 amino acids (38 kDa), and A1-A, the shorter variant, missing residues 253 to 303 (320 aa, 34 kDa), which, in most tissues, is over 20-times more abundant than the full-length protein. Structurally, hnRNP A1 can be divided in an N-terminal domain that contains two closely-related RRM domains, followed by a highly flexible glycine-rich (Gly-rich) C-terminal region, which contains an RGG box RNA binding domain and a nuclear targeting sequence, termed M9 (Figure 1) [19]. Although the secondary structure of the full-length hnRNP A1 has not been confirmed experimentally, the N-terminal, termed the UP1 fragment, has been extensively studied by Z-ray crystallography and NMR spectroscopy [20]. Several high-resolution crystal structures of the two tandem RRMs of hnRNP A1 have been solved both in their free form and bound to telomeric DNA repeats at a resolution of 1 Å [21–25]. Eukaryotic RRMs are composed of four β-strands sheets and two α-helices positioned in a β1α1β2β3α2β4 structure and
characterized by two highly conserved sequences, RNP1 (octamer) and RNP2 (examer), which are located about 30 residues apart [4]. The conserved RNP1 and RNP2 sequences are juxtaposed on the β3 and β1 strands and make direct contact with the RNA. The β-sheet surface of the RRM constitutes a free plane that functions as a platform for RNA binding. The variable regions of the loops connecting the β-strands and the terminal regions of the RRM have been shown to be important determinants of RNA-binding specificity [26]. These regions differ in amino acid sequence among single hnRNP proteins, thus contributing to the differences in their RNA binding specificities. In spite of their similar sequences and overall structure, the two RRMs of hnRNP A1 are neither redundant nor functionally equivalent. It is unclear how these RRMs contribute to the RNA binding properties of hnRNP A1, since duplications, deletions or swapping of the RRMs differently affects the alternative splicing functions of hnRNP A1 [27].

Figure 1. Structural features of nuclear ribonucleoprotein (hnRNP) A1. (A) Schematic map of the two hnRNP A1 isoforms. Acetylation (A), phosphorylation (P) and SUMOylation (S) sites are labeled; (B) Schematic representation of hnRNP A1 structural and functional domains.

The Gly-rich 124 amino acid C-terminal domain has been shown to have both RNA and protein binding properties [28]. The Gly-rich domain contains a motif characterized by closely spaced clusters of Arg-Gly-Gly tripeptide repeats with interspersed aromatic (Phe, Tyr) residues, named the RGG box, which is thought to confer RNA binding functions to this domain [29]. Although the precise contribution of the RGG box to the overall RNA binding activity of hnRNP A1 is not well understood, experimental data indicate that it is responsible for cooperative binding of hnRNP A1 to its target RNA [30,31]. The Gly-rich domain is also required for homologous and heterologous interactions between hnRNP A1, other hnRNPs and RNA binding proteins [32]. The complexity and number of these interactions underline hnRNP A1 functions in RNA biogenesis [28,33], export [34] and telomere regulation [35].

Downstream of the RGG box and within the Gly-rich domain of hnRNP A1 is located a 38-amino acid nucleo-cytoplasmic shuttling (NS) domain, called M9 [36]. Like many of the hnRNP proteins, hnRNP A1 is predominantly nuclear at steady-state, but can shuttle between the nucleus and the cytoplasm in response to specific signals [37,38]. The M9 domain is both necessary and sufficient to confer nuclear localization and does not bear resemblance to the classical nuclear localization signal (NLS). Interestingly, this domain also acts as a nuclear export signal, allowing export and cytoplasmic accumulation of hnRNP A1 in response to specific signals [34]. The nuclear shuttling
activity of hnRNP A1 is mediated by the direct interaction of the M9 sequence with two transport receptors of the karyopherin-β family, Transportin 1 and 2 (Trn1, Trn2) [39–41].

The interaction of hnRNP A1 with nucleic acids was first observed in early attempts to identify eukaryotic DNA-binding proteins [42]. Initial studies showed that both the RRM and Gly-rich domains of hnRNP A1 are involved in binding single-stranded and double-stranded DNA sequences [29,43]. These interactions are dependent on salt concentration, temperature and the methylation state of residues within the Gly-rich domain [44,45]. The affinity of hnRNP A1 for RNA sequences was established shortly after the initial discovery of its DNA binding abilities. Specific RNA sequences recognized by hnRNP A1 were isolated utilizing pools of interacting oligos by a SELEX procedure [46]. These RNA sequences shared the common UAGGGA(U) motif. Subsequent studies showed a clear affinity of hnRNP A1 for AUUUA-rich sequences contained within the 3'-untranslated region (UTR) of several eukaryotic genes [47]. Later, a number of functional hnRNP A1 binding sites were identified in several transcripts characterized by the UAGA(G) motif [17,48–52].

Post-translational modification in hnRNP A1 includes methylation, phosphorylation and SUMOylation. Many arginine residues within the RGG box are sites for methylation, which act to modulate nucleic acids binding [45,53,54]. Several serine residues in both RRM s and the Gly-rich domain have been shown to be phosphorylated both in vitro and in vivo [55–59]. Protein kinase C (PKC) and Mitogen-Activated Protein Kinase (MAP)-Interacting Kinases (MNKs) have been shown to phosphorylate a series of serine residues and to reduce hnRNP A1’s ability to bind specific RNA sequences and to regulate its localization [38,55–57]. hnRNP A1 also includes a SUMOylation site within the second RRM and appears to be SUMOylated in vivo, although the functional significance of this modification is unknown [60].

The RNA, DNA and protein binding specificities of hnRNP A1 define several functions in eukaryotic RNA maturation, maintenance, expression and genome stability. In the following sections, we will describe recent advances in our understanding of the functions of this protein in global gene expression and cellular metabolism.

4. Transcriptional Functions of hnRNP A1

hnRNP A1 has been shown to associate with multiple promoter sequences and to participate in the regulation of transcriptional events, although the precise mechanism is unclear. Association of hnRNP A1 with the promoters of genes coding for thymidine kinase (TK) [61], γ-fibrinogen [62] and the vitamin D receptor [43] induces transcriptional repression, while it functions as an activator upon binding onto the ApoE [63] and, possibly, the protein kinase regulated by RNA (PKR) [64] promoters. The ability of hnRNP A1 to bind G-quadruplex DNA structures [65,66] could also facilitate transcription by destabilizing and unwinding the G-quadruplex structure at the promoter of several genes. G-quadruplex formations in the human KRas and c-myc promoters are located nearby binding sites for hnRNP A1 [67,68]. It is conceivable that hnRNP A1 binding could relax the quadruplex DNA structure, promoting transcription initiation. An alternative mechanism might involve the 7SK small nuclear ribonucleoprotein (7SK snRNP), a molecular scaffold containing the non-coding 7SK small nuclear RNA (7SK), which binds the cellular factors, HEXIM1, HEXIM2 and LARP7, enabling the sequestration and inhibition of the transcription elongation factor, P-TEFb [69]. hnRNP A1 has been
shown to bind the 7SK RNA, promoting disassociation of P-TEFb from the 7SK snRNP and its assembly onto the active RNA polymerase II (RNAPII) transcription complex, thus activating gene transcription [70,71]. In addition to modulating transcriptional events through binding DNA and RNA sequences, hnRNP A1 can also directly regulate the activity of transcription factors through protein-protein interactions. hnRNP A1 has been shown to interact with the inhibitory subunit of NF-κB alpha (IκBa) through its N-terminal RNA-binding domain, resulting in the activation of nuclear factor κ B (NF-κB) [72].

5. The Role of hnRNP A1 in Constitutive and Alternative mRNA Splicing

The removal of intronic sequences in the nascent transcript is carried out by the sequential assembly of a large multicomponent ribonucleoprotein complex, the spliceosome, constituted by five core small nuclear ribonucleoproteins (snRNPs, U1, U2, U4, U5, U6) [73,74], whose assembly onto the pre-mRNA requires several auxiliary splicing factors [75,76]. Exons from a primary transcript can be spliced in different arrangements to yield mRNAs that will produce functionally different protein variants [77,78]. The sequencing of the human genome and transcriptome has revealed that over 90% of multi-exon genes are alternatively spliced in tissue-specific and developmentally-regulated manners, providing a major mechanism for the regulation of gene expression [79–81]. 5' splice sites (5' ss) and 3' splice sites (3' ss) are short, loosely conserved sequences flanking the introns, which are required for splicing, but alone are not sufficient for the proper recognition of exonic and intronic sequences. Additional regulatory elements are classified as either exonic and intronic splicing enhancers (ESE and ISE) or exonic and intronic splicing silencers (ISS and ESS). Positive and negative cis-acting sequences are often organized in multipartite control elements. The best-known splicing silencers are dependent on interactions with the hnRNPs of the A/B and H/F sub-families [82], while the best characterized exonic splicing enhancers are purine-rich sequences that recruit members of the serine/arginine-rich (SR) family of splicing activators. SR-dependent ESEs act by recruiting and stabilizing components of the core splicing machinery to nearby splice sites [83]. SR proteins and hnRNPs often play counteracting roles within the same splicing regulatory unit composed by clusters of several, often overlapping, ESSs and ESSs [15,18,84].

A constitutive role for hnRNP A1 in the multi-step process, leading to the catalytic excision of the intervening intron and joining of the adjacent exons, is suggested by comprehensive proteomic analysis of splicing complexes, indicating that this protein participates in all steps of spliceosome assembly [76,85]. Further proof for a role of hnRNP A1 in the activity of the basic splicing machinery is given by recent results showing that it forms a ternary complex with the essential splicing factor, U2AF, and helps the splicing machinery discriminating between cryptic and functional 3' splice sites [86].

hnRNP A1’s role as a modulator of alternative splicing has been widely studied. hnRNP A1 was initially identified as a switch for splicing site selection using model and adenovirus E1A pre-mRNAs [87] and quickly became the most studied splicing repressors in both cellular and viral systems. Experimental observations in several genes (summarized in Table 1) established a key role for hnRNP A1 in a number of cellular mechanisms regulating development and a number of cellular responses to endogenous and exogenous stimuli and disease. Binding of hnRNP A1 to several
high-affinity exonic and intronic sequences has been identified as essential for repression of splicing in human and viral genes. Biochemical and structural studies have uncovered several mechanisms utilized by hnRNP A1 to modulate splicing: (i) In some alternatively spliced exons, hnRNP A1-dependent ESSs overlap ESEs bound by SR proteins, which promote spliceosome assembly, and the competition between hnRNP A1 and SR proteins for common binding sites determines the ratio of inclusion/exclusion of the exon (Figure 2A). Examples of this type of regulation are the HipK3 germline-specific exon [88], the bovine growth hormone exon 5 [89,90], the c-src exon N1 [91], the HIV-1 tat exon 2 [18] and the SMN2 exon 7 [92,93]; (ii) In other cases, when hnRNP A1-dependent ESSs and SR-dependent ESEs do not overlap, hnRNP A1 can bind cooperatively along the exon, limiting the access of SR proteins or other splicing factors to their binding sites (Figure 2B). Detailed work on the mechanism of hnRNP A1 cooperative binding showed that, after binding to a high-affinity site, hnRNP A1 spreads preferentially in a 3' to 5' direction and can displace other bound proteins from the RNA to repress splicing [94]; (iii) Specific binding sites for hnRNP A/B proteins also exist in introns and may inhibit the binding of the key splicing regulator onto nearby intronic regions. Inclusion of exon 2 and 3 of the IRF-3 gene is dependent on an ISS binding hnRNP A1 within the first intron of the gene. The hnRNP binding site is located in proximity of a series of ISEs bound by the SR protein, SF2. hnRNP A1 binding is likely to displace SF2 and downregulate splicing of the downstream exons (Figure 2C) [95]. This is similar to the mechanism regulating splicing of HIV-1 tat exon 2, where an hnRNP A1-dependent ESS is juxtaposed to an ESE recognized by the SR protein, SC35 [18]. In a different system, the HIV-1 tat exon 3' upstream intron, hnRNP A1 binds an ISS that overlaps a branch point. This is a conserved sequence located upstream of the 3' splice site that is bound by the U2 snRNP and is required for spliceosome assembly and efficient excision of the intron. hnRNP A1 binding onto the ISS competes with the U2 snRNP recognition of the branch point and inhibits spliceosome assembly [96]. (iv) An alternative “looping out mechanism” has been proposed for the alternative splicing of the hnRNP A1 exon 7B, which is flanked by multiple binding sites for hnRNP A1. Binding of hnRNP A1 onto the ISSs promotes the skipping of exon 7b. It is postulated that hnRNP A1 molecules bound at both sides of exon 7b can interact through their Gly-rich domain and loop out the intervening exon (Figure 2D) [16,97,98]. hnRNP A1 binding sites are found flanking several alternatively-spliced eukaryotic exons and often co-localize with binding sites for members of the hnRNP H/F protein family. hnRNP A1 and hnRNP H have been shown to have the potential to collaborate to modulate splicing by interacting through their Gly-rich domain [15,28].

Table 1. hnRNP A1 role in alternative splicing. 3' ss, 3' splice site.

| Gene                                      | Organism | Splicing event | Reference |
|-------------------------------------------|----------|----------------|-----------|
| Medium-chain acyl-CoA dehydrogenase (MCAD) | Human    | Exon 11 skipping | [99]      |
| Myelin-associated glycoprotein (MAG)      | Human    | Exon 12 skipping | [100]     |
| Interferon regulatory factor-3 (IRF-3)    | Human    | Exons 2 and 3 skipping | [95] |
| TNF Receptor Superfamily Member 6 (Fas)   | Human    | Exon 6 skipping  | [101]     |
| Ras-related C3 botulinum toxin substrate 1 (Rac1) | Human    | Exon 3b skipping | [102]     |
Table 1. Cont.

| Gene                                      | Organism     | Splicing event            | Reference       |
|-------------------------------------------|--------------|---------------------------|-----------------|
| Insulin receptor gene (INSR)              | Human        | Exon 11 skipping          | [103]           |
| Breast cancer 1 (BRC41)                   | Human        | Exon 18 skipping          | [104]           |
| Breast cancer 1 (BRC41)                   | Human        | Exon 6 skipping           | [105]           |
| Homeodomain interacting protein kinase 3 (HIPK3) | Human       | Testis-specific           | [88]            |
| Bovine growth hormone (BGH)               | Bovine       | Exon 5 skipping           | [89,90,106]     |
| Survival of Motor Neuron 2, (SMN2)        | Human        | Exon 7 skipping           | [92,107–110]    |
| Fibroblast growth factor receptor 2 (FGFR2) | Human        | K-SAM exon skipping       | [111,112]       |
| Amyloid precursor protein (APP)           | Human        | Exon 7 and 8 skipping     | [113]           |
| Dystrophin                                | Human        | Exon 31 skipping          | [114]           |
| β-tropomyosin                             | Chicken      | Exon 6B skipping          | [115]           |
| pX region                                 | Human        | Exon skipping             | [116]           |
| V-Ha-ras Harvey rat sarcoma viral oncogene homolog (C–H-ras) | Human | Exon IDX skipping         | [117]           |
| Proto-oncogene tyrosine-protein kinase Src (c-SRC) | Human | Exon N1 skipping          | [91]            |
| Trans-activator of transcription (Tat)    | Human        | Exon 3 3’ ss repression   | [48,51,94,96,118]|
| Trans-activator of transcription (Tat)    | Human        | Exon 2 3’ ss repression   | [18,49]         |
| Carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) | Human | Exon 7 skipping           | [119]           |
| heterogeneous ribonucleoprotein A1 (hnRNP A1) | Human | Exon 7B skipping          | [16,97,98]      |
| Pyruvate kinase (PKM)                     | Human        | Exon 9 skipping           | [120]           |
| Viral protein R (VPR)                     | Human        | Repression 3’             | [121]           |
| E6/E7                                     | Human papillomavirus type-16 (HPV-16) | E6 exon skipping       | [122]           |

Functional and physical interactions with a number of other splicing regulators are also possible and might contribute to the alternative splicing functions of hnRNP A1 [123]. Recent studies on the splicing activities of six hnRNPs (A1, A2/B1, H1, F, U and M) carried out utilizing a genomic approach show that, although the high degree of homology present between hnRNP A1 and A2/B1, hnRNPs A2/B1, H1, F and U act cooperatively to regulate the same set of alternative splicing events, hnRNPs A1 and M frequently influence changes in opposition to the other hnRNP proteins [11]. The growing amount of data obtained through genomic, cellular and molecular approaches indicate that regulation of alternative splicing by hnRNP A1 is pervasive throughout the human transcriptome and utilizes a number of mechanisms in synergy with several other splicing factors.
Figure 2. Splicing regulation mechanisms of hnRNP A1. (A) Serine/arginine-rich (SR) proteins bound to an exonic splicing enhancer (ESE) promote recruitment of splicing factors to nearby splice sites. Binding of hnRNP A1 to an exonic splicing silencer (ESS) overlapping an ESE displaces the SR proteins and promotes skipping of the exon from the mRNA [18,88–93]. (B) hnRNP A1 binding to a high affinity binding site, which functions as an ESS, promotes cooperative binding of other hnRNP A1 molecules along the transcript. This inhibits the binding of SR proteins and other splicing factors and promotes exclusion of the exon from the mRNA [94]; (C) Binding of hnRNP A1 to an intronic splicing silencer (ISS) overlapping an SR-dependent intronic splicing enhancer (ISE), or the branch point (bp) displaces SR proteins or the U2 snRNP and inhibits splicing of the downstream exon [18,95,96]; (D) The interaction among hnRNP A1 proteins bound to ISS upstream and downstream the alternatively spliced exon promotes looping-out and exclusion of the exon [16,97,98].

6. hnRNP A1, Telomeres Maintenance and Telomerase Activity

hnRNP A1 also plays a role in DNA metabolism associated with telomeres, contributing to telomere length regulation and maintenance. Telomeres are conserved tandem arrays of repetitive DNA sequences (TTAGGG in vertebrates) that function by interacting with a number of proteins and protecting the ends of chromosomes from being detected as broken DNA by the repair system, thus preventing degradation and fusion [124]. Human telomeres end with a 3' single-stranded G-rich overhang of 12–300 nucleotides, which invade the homologous double-stranded telomere to create a
telomere loop structure (t-loop) with the help of a complex of telomere-bound proteins, termed shelterin [125]. The single-stranded G-rich overhang can also induce G-quadruplex formation [126] and, during development and in some cell types, including cancer and stem cells, provides the substrate required for elongation by telomerase, a ribonucleoprotein that possesses reverse transcriptase activity (TERT), capable of catalyzing the addition of telomere repeats utilizing an internal RNA template [124].

In most human somatic cells, telomeres shorten as cells divide, and failure to maintain telomeres induces cell cycle arrest, senescence and apoptosis. Failure of the mechanisms detecting the shortening of telomeres leads to chromosome instability and may trigger malignant transformation [127]. hnRNP A1 has been shown to bind telomeric sequences and plays a critical role in telomere biogenesis [24] and maintenance by promoting telomerase activity and telomere length extension. In vitro depletion of hnRNP A1 from human cell extracts reduces telomerase activity, which is fully recovered upon addition of purified recombinant hnRNP A1 [128]. Similar results have been also achieved in in vivo models, showing that telomeres are shorter in an hnRNP A1-deficient murine cell line, and addition of hnRNP A1 restores telomere length [129]. It has been proposed that hnRNP A1 might contribute to the telomerase function by its ability to unwind the G-quadruplex structures of telomeres [128] and, at the same time, bind the RNA component of the telomerase [130] and TERRA, the RNA component of the telomere complex [131]. Recent work also suggests that hnRNP A1 facilitates telomeric end-capping following replication upon phosphorylation by the DNA-PKcs kinase [35,132].

Although most of the studies indicate a positive role in telomere elongation for hnRNP A1, in vitro data suggest that the binding of hnRNP A1 to the single-stranded telomeric ends protects such sequences against degradation and, at the same time, inhibits the telomerase activity [133]. The multiple functions assigned to hnRNP A1 in telomere maintenance and elongation indicate that hnRNP A1 might play different roles, depending on its phosphorylation state or the presence of other co-factors.

7. mRNA Nuclear Export and hnRNP A1

hnRNP A1 is found to be associated with poly(A)+ RNA in both the nucleus and cytoplasm [134] and is one of the components of the hnRNP complex that accompanies mature transcripts through the nuclear pores [37], and it associates with mRNA export factors [134]. The shuttling properties of hnRNP A1 are dependent on the M9 sequence that functions as both a nuclear export and a nuclear localization signal [135].

In vitro and in vivo observations suggest a role for hnRNP A1 in the nuclear export of a number of mRNAs. Detailed analysis of mRNA trafficking through the nuclear pores carried out utilizing dihydrofolate reductase (DHFR) gene transcripts indicates that expression of hnRNP A1 or M9 peptides inhibits mRNA export [136,137], while electron microscopy studies and, more recently, light sheet microscopy showed that hnRNP A1-like proteins bind to the giant Balbiani ring mRNA in Chironomus tentans and accompany this mRNA to the cytoplasm [138,139]. Inhibition of RNA polymerase II in HeLa cells by actinomycin D and the study of transcriptionally inactive mouse embryos also indicate that newly synthesized mRNA acts as an inducer for the nuclear import of hnRNP A1 [37,140]. Together, these data are consistent with the notion that hnRNP A1 plays a role in
mRNA export. Nevertheless, data showing that hnRNP A1 antibodies efficiently immunoprecipitate excised introns, but not the spliced transcripts, suggest a role in packaging intronic sequences, which are retained within the nucleus after splicing and, ultimately, degraded [141]. Thus, it is still unclear if hnRNP A1 plays a passive role in mRNA export, a more active one, by packaging excised introns and retaining them in the nucleus, or if it is involved in the export of only specific mRNAs subsets. It is plausible that this protein might exert multiple roles in mRNA nuclear retention and export depending on its phosphorylation state, relative expression levels and interactions with other cellular partners.

8. hnRNP A1 Regulates mRNA Translation and Turnover

hnRNP A1 also plays roles in modulating the expression of fully processed mRNAs. AU-rich sequences (AREs), which have been shown to modulate mRNA turnover and translation in a number of mRNAs [142], are specifically bound by hnRNP A1 in the mRNAs coding for interleukin 2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), suggesting a role in regulating mRNA stability for this protein [143,144].

hnRNP A1 activities in both cap-dependent and cap-independent translation mechanisms have also been observed. Addition of hnRNP A1 in a rabbit reticulocyte lysate rendered translation cap-dependent, possibly by promoting ribosome binding at the m7G cap, preventing initiation at aberrant translation start sites [145]. In cap-independent translation systems, hnRNP A1 has been shown to bind internal ribosomal entry site (IRESs) sequences, which govern cap-independent translation initiation in cellular and viral mRNAs [146]. The assembly of hnRNP A1 onto IRESs has been shown to enhance IRES-mediated translation of the human fibroblast growth factor 2 (FGF-2) mRNA [147], the human rhinovirus (HRV) [148] and, more recently, the transcription factor, SREBP-1 (sterol-regulatory-element-binding protein 1) in hepatocytes [149]. Studies on the expression of the cyclin D1 and c-myc mRNAs show that hnRNP A1 constitutively binds and promotes translation from the IRES of both genes, and this activity is negatively modulated by phosphorylation of hnRNP A1 by the Akt kinase [150,151]. Interestingly, in a few other systems, such as the X-linked inhibitor of apoptosis (XIAP) mRNA [152] and the human apoptotic peptidase activating factor 1 (apaf-1) [148], hnRNP A1 has been shown to inhibit IRES-mediated translation. These, apparently contradictory, data suggest that the role of hnRNP-A1 in translation is dependent on other co-factors, which might modify its activity in different systems.

9. hnRNP A1 Regulates miRNA Processing

Given hnRNP A1’s ubiquitous RNA binding properties and its ability to interact with a number of cellular factors, it is not surprising that it has a role in the processing of a number of miRNAs, short non-coding RNAs that act as regulators of gene expression in many different biological processes [153]. miRNAs base-pair with target mRNAs and negatively regulate their expression by two mechanisms: reducing the efficiency of translation and shortening the transcript half-life by recruiting an enzymatic complex called the RNA-induced silencing complex (RISC). The biogenesis of mature miRNAs is a multistep process that initiates in the nucleus. After transcription, the pri-miRNA precursors are cleaved by the RNase III Drosha enzyme and DGCR8, which results in the production of stem loop precursors, termed pre-miRNAs. Following export to the cytoplasm, the pre-miRNAs are processed by
the type III ribonuclease, Dicer, resulting in the production of mature miRNAs that are then loaded onto the RISC complex [154].

The crosslinking and immunoprecipitation protocol (CLIP) carried out to search for hnRNP A1 endogenous RNA targets has revealed that this protein binds specifically to human pri-miR-18a [155]. A detailed biochemical analysis revealed that hnRNP A1 facilitates miR-18a production by binding to the terminal loop of its pri-miRNA and induces a relaxation at the stem, creating a more favorable cleavage site for Drosha, thus acting as an auxiliary factor for the processing of the miRNA precursor [155]. It is unclear if this regulatory mechanism is common to other miRNAs; nevertheless, phylogenetic data suggests that a class of miRNAs might be regulated by the interactions with hnRNP A1 and other RNA binding factors [156]. Surprisingly, recent results revealed that hnRNP A1 negatively regulates expression of the human Let-7a, a member of the Let-7 family of miRNAs, which is present in multiple copies in different genomes and plays roles in cancer and pluripotency by targeting several genes [157]. hnRNP A1 binds the conserved terminal loop of pri-let-7a and inhibits its processing by Drosha, thus acting as a negative regulator of miRNA expression [158]. The effect of hnRNP A1 on Let-7a expression is the opposite of that on miR-18a, thus acting as a negative regulator of miRNA expression. Consistent with this observation, the molecular mechanisms regulating these two systems differ. Instead of facilitating pri-Let-7a processing by Drosha, hnRNP A1 binding to the pri-Let-7a loop interferes with the binding of the splicing regulatory protein, KSRP, known to promote Let-7a biogenesis [159]. Therefore, hnRNP A1 and KSRP play antagonistic roles in the post-transcriptional regulation of Let-7a by competing for overlapping binding sites within the conserved loop of pri-Let-7a. While the role of hnRNP A1 in controlling miRNA biogenesis has been studied, little is known of the hnRNP-targeted miRNAs. Studies focused on the isolation and functional characterization of such targets may uncover additional relevant regulatory pathways modulated by hnRNP A1.

10. hnRNP A1 Role in Human Disease and Therapy

Given its multiple functions in gene expression and cellular metabolism, hnRNP A1 has been shown to play a key role in human disease. A number of studies utilizing biochemical, cellular, animal and, more recently, genomic approaches have unveiled the roles of hnRNP A1 in genetic deficiencies, cancer development, metastasis, neurodegeneration and replication of viral pathogens.

The relevance in disease of hnRNP A1 is highlighted by its deregulated, usually over-overexpression, in a wide variety of cancers, including breast, colorectal, lung and gliomas [120,160–165], and has been found to promote tumor invasion and to be connected to poor prognosis in hepatocellular carcinoma [166]. Consistent with its role in oncogenesis, siRNA-mediated knockdown of hnRNP A1 in cancer cells results in apoptosis [167], while its expression has antiapoptotic effects, possibly by affecting splicing of caspase-2 pre-mRNA [168].

hnRNP A1 plays several key roles in neuronal functions, and since its expression causes drastic changes in RNA metabolism, variation in its abundance contributes to neurodegenerative diseases, such as Alzheimer’s disease (AD), spinal muscular atrophy (SMA), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), fronto-temporal lobar degeneration (FTLD), HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hereditary spastic paraparesis (HSP) [169].
Alzheimer disease patients exhibit a reduction of hnRNP A1 expression in the brain, and in a mice model, loss of hnRNP A1 is associated with impaired cognitive function [170]. HnRNP A1 has also been shown to modulate alternative splicing of the APP gene, affecting the generation of toxic Aβ peptide, which accumulates in the amyloid plaques characteristic of the Alzheimer disease brain [113]. The inverse changes in hnRNP A1 levels in tumors and neurodegenerative diseases might point out key differences in the molecular pathologies of such diseases.

An intriguing recent report shows that hnRNP A1 might function as a prion-like protein, inducing a series of pathogenesis through a unique and novel mechanism [100]. Families with inherited degeneration affecting muscle, brain, motor neuron, bone and amyotrophic lateral sclerosis carry distinctive mutations within the hnRNP A1 Gly-rich domain. The ability of hnRNP A1 to multimerize is enhanced by the mutations detected in patients. Furthermore, the mutated protein can increase the ability of the wild-type hnRNP A1 to multimerize into fibrils and, in an animal model, the formation of cytoplasmic inclusion. Thus, hnRNP A1 could be an important component of human proteinopathies.

Although many human pathologies and physiological responses correlate with a change in the expression level of hnRNP A1, little is known of the mechanisms regulating the abundance of this protein. Analysis of the cellular targets of the RNA binding protein, Quaking (Qk), which is required for myelin formation and associated with psychiatric disease, showed that the 3’ UTR of the hnRNP A1 messenger contains a binding site for this protein [171]. Qk regulates the overall level of hnRNP A1 by stabilizing its mRNA. Genome-wide analyses showed that hnRNP A1 contributes to Qk control of myelin gene expression, thus consolidating a role for hnRNP A1 in neural pathogenesis.

hnRNP A1 has also been shown to participate in the mechanisms regulating the gene expression and replication of a number of viruses: human rhinovirus [148], Enterovirus 71 [172], Sindbis virus [173], hepatitis C virus [174], human papilloma virus [175,176] and, more extensively, HIV-1 [177,178]. The role played by hnRNP A1 in HIV-1 gene expression has been widely studied and has been utilized as a model to elucidate the mechanisms regulating cellular mRNA processing. Biochemical, structural and cellular approaches have identified multiple high-affinity hnRNP A1 binding sites within the viral transcript. The interaction of hnRNP A1 with the viral transcript and the interplay with other cellular splicing factors tightly regulate a series of splicing events that generate over 40 mRNAs from the single viral transcript. Furthermore, hnRNP A1 acts to upregulate IRES-mediated translation initiation of the viral mRNA [179] and possibly stimulates the export through the nuclear pore complex [180].

The development of reagents and compounds that specifically target the activity of hnRNP A1 might be of great help in the development of novel therapeutics for a number of diseases and pathogens. Targeting the splicing activity of hnRNP A1 has been recently exploited in the treatment of spinal muscular atrophy (SMA), a neurodegenerative disease in which cellular death of spinal cord motor neurons results in system-wide muscle atrophy [181]. SMA is caused by loss of the Survival Motor Neuron 1 (SMN) protein, due to mutation within the SMN1 gene. SMN2 is a paralogous gene that produces a low level of the SMN protein, due to the presence of a mutation, which creates a novel hnRNP A1 binding site, which, in turn, induces alternative splicing of an exon, generating an mRNA coding for a defective SMN protein [92]. Recent work in cellular and animal models showed that antisense oligonucleotide analogs masking the hnRNP A1-dependent splicing regulatory sequence in SMN2 correct the splicing event and induce the production of functional SMN proteins [182–185].
A different approach has been recently utilized to inhibit proliferation and migration of a hepatoma cell line. hnRNP A1 is highly expressed in liver cancer tissues compared with either para-cancer or benign controls. Expression of an hnRNP A1-specific single-stranded DNA aptamer blocked hnRNP A1 activity and showed a stronger inhibitory effect on the proliferation of cultured hepatoma cells than hnRNP A1-specific small interfering RNAs [186].

11. Conclusions

hnRNP A1 is a multifunctional protein with unique properties that exerts its activities on a wide range of cellular processes. This protein regulates several aspects of mRNA biogenesis, such as transcription, constitutive and alternative splicing, nuclear export and turnover and, at the same time, influences the translation and telomerase machineries. While hnRNP A1 appears to have a constitutive role in some of those processes, it also exerts a specific regulatory function on a number of genes with key functions in health and disease. Intriguing new therapeutic approaches aimed at regulating the expression and functions of hnRNP A1 on specific target mRNAs are being developed. Given the multifunctional nature of this protein, it is difficult to predict the specificity and efficiency of putative new drugs aimed at altering its expression patterns and activities. Nevertheless, novel compounds aimed at masking hnRNP A1 binding sites onto specific substrates are showing promising results.

The identification of the other cellular factors that functionally and physically interact with this protein in a spatial and temporal manner will be of great help to better understand the hnRNP A1 roles in multiple aspects of gene regulation. Genomic and proteomic tools will be essential in developing assays aimed at the identification of the interacting molecules and the functional mapping of hnRNP A1 cellular targets.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Dreyfuss, G.; Matunis, M.J.; Piñol-Roma, S.; Burd, C.G. hnRNP proteins and the biogenesis of mRNA. Ann. Rev. Biochem. 1993, 62, 289–321.
2. Beyer, A.L.; Christensen, M.E.; Walker, B.W.; LeStourgeon, W.M. Identification and characterisation of the packaging proteins of core 40S hnRNP particles. Cell 1977, 11, 127–138.
3. Piñol-Roma, S.; Choi, Y.D.; Matunis, M.J.; Dreyfuss, G. Immunopurification of heterogeneous nuclear ribonucleoprotein particles reveals an assortment of RNA binding proteins. Genes Dev. 1988, 2, 215–227.
4. Dreyfuss, G.; Philipson, L.; Mattaj, I.W. Ribonucleoprotein particles in cellular processes. J. Cell Biol. 1988, 106, 1419–1425.
5. Kiledjian, M.; Dreyfuss, G. Primary structure and binding activity of the hnRNP U protein: Binding RNA through RGG box. EMBO J. 1992, 11, 2655–2664.
6. Burd, C.G.; Dreyfuss, G. Conserved structures and diversity of functions of RNA-binding proteins. Science (N. Y.) 1994, 265, 615–621.
7. Han, S.P.; Tang, Y.H.; Smith, R. Functional diversity of the hnRNPs: Past, present and perspectives. *Biochem. J.* **2010**, *430*, 379–392.

8. Dreyfuss, G.; Kim, V.N.; Kataoka, N. Messenger-RNA-binding proteins and the messages they carry. *Nat. Rev. Mol. Cell Biol.* **2002**, *3*, 195–205.

9. Singh, R.; Valcarcel, J. Building specificity with nonspecific RNA-binding proteins. *Nat. Struct. Mol. Biol.* **2005**, *12*, 645–653.

10. Kamma, H.; Portman, D.S.; Dreyfuss, G. Cell type specific expression of of hnRNP proteins. *Exp. Cell Res.* **1995**, *221*, 187–196.

11. Huelga, S.C.; Vu, A.Q.; Arnold, J.D.; Liang, T.Y.; Liu, P.P.; Yan, B.Y.; Donohue, J.P.; Shiue, L.; Hoon, S.; Brenner, S.; *et al.* Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. *Cell Rep.* **2012**, *1*, 167–178.

12. Dangli, A.; Plomaritoglou, A.; Boutou, E.; Vassiliadou, N.; Moutsopoulos, H.M.; Guialis, A. Recognition of subsets of the mammalian A/B-type core heterogeneous nuclear ribonucleoprotein polypeptides by novel autoantibodies. *Biochem. J.* **1996**, *320*, 761–767.

13. Kamma, H.; Horiguchi, H.; Wan, L.; Matsui, M.; Fujiwara, M.; Fujimoto, M.; Yazawa, T.; Dreyfuss, G. Molecular characterization of the hnRNP A2/B1 proteins: Tissue-specific expression and novel isoforms. *Exp. Cell Res.* **1999**, *246*, 399–411.

14. Huang, M.; Rech, J.E.; Northington, S.J.; Flicker, P.F.; Mayeda, A.; Krainer, A.R.; LeStourgeon, W.M. The C-protein tetramer binds 230 to 240 nucleotides of pre-mRNA and nucleates the assembly of 40S heterogeneous nuclear ribonucleoprotein particles. *Mol. Cell. Biol.* **1994**, *14*, 518–533.

15. Han, K.; Yeo, G.; An, P.; Burge, C.B.; Grabowski, P.J. A combinatorial code for splicing silencing: UAGG and GGGG motifs. *PLoS Biol.* **2005**, *3*, e158.

16. Hutchison, S.; LeBel, C.; Blanchette, M.; Chabot, B. Distinct sets of adjacent heterogeneous nuclear ribonucleoprotein (hnRNP) A1/A2 binding sites control 5′ splice site selection in the hnRNP A1 mRNA precursor. *J. Biol. Chem.* **2002**, *277*, 29745–29752.

17. Chabot, B.; Blanchette, M.; Lapierre, I.; la Branche, H. An intron element modulating 5′ splice site selection in the hnRNP A1 pre-mRNA interacts with hnRNP A1. *Mol. Cell. Biol.* **1997**, *17*, 1776–1786.

18. Zahler, A.M.; Damgaard, C.K.; Kjems, J.; Caputi, M. SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. *J. Biol. Chem.* **2004**, *279*, 10077–10084.

19. He, Y.; Smith, R. Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B. *Cell. Mol. Life Sci.* **2009**, *66*, 1239–1256.

20. Barraud, P.; Allain, F.H. Solution structure of the two RNA recognition motifs of hnRNP A1 using segmental isotope labeling: How the relative orientation between RRMs influences the nucleic acid binding topology. *J. Biomol. NMR* **2013**, *55*, 119–138.

21. Xu, R.M.; Jokhan, L.; Cheng, X.; Mayeda, A.; Krainer, A.R. Crystal structure of human UP1, the domain of hnRNP A1 that contains two RNA-recognition motifs. *Structure* **1997**, *5*, 559–570.
22. Shamoo, Y.; Krueger, U.; Rice, L.M.; Williams, K.R.; Steitz, T.A. Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 Å resolution. *Nat. Struct. Biol.* **1997**, *4*, 215–222.

23. Vitali, J.; Ding, J.; Jiang, J.; Zhang, Y.; Krainer, A.R.; Xu, R.M. Correlated alternative side chain conformations in the RNA-recognition motif of heterogeneous nuclear ribonucleoprotein A1. *Nucleic Acids Res.* **2002**, *30*, 1531–1538.

24. Ding, J.; Hayashi, M.K.; Zhang, Y.; Manche, L.; Krainer, A.R.; Xu, R.M. Crystal structure of the two-RRM domain of hnRNP A1 (UP1) complexed with single-stranded telomeric DNA. *Genes Dev.* **1999**, *13*, 1102–1115.

25. Myers, J.C.; Shamoo, Y. Human UP1 as a model for understanding purine recognition in the family of proteins containing the RNA recognition motif (RRM). *J. Mol. Biol.* **2004**, *342*, 743–756.

26. Gorlach, M.; Wittekind, M.; Beckman, R.A.; Mueller, L.; Dreyfuss, G. Interaction of the RNA-binding domain of the hnRNP C proteins with RNA. *EMBO J.* **1992**, *11*, 3289–3295.

27. Mayeda, A.; Munroe, S.H.; Xu, R.M.; Krainer, A.R. Distinct functions of the closely related tandem RNA-recognition motifs of hnRNP A1. *RNA (N. Y.)* **1998**, *4*, 1111–1123.

28. Fisette, J.F.; Toutant, J.; Dugre-Brisson, S.; Desgroseillers, L.; Chabot, B. hnRNP A1 and hnRNP H can collaborate to modulate 5' splice site selection. *RNA (N. Y.)* **2010**, *16*, 228–238.

29. Nadler, S.G.; Merrill, B.M.; Roberts, W.J.; Keating, K.M.; Lisbin, M.J.; Barnett, S.F.; Wilson, S.H.; Williams, K.R. Interactions of the A1 heterogeneous nuclear ribonucleoprotein and its proteolytic derivative, UP1, with RNA and DNA: Evidence for multiple RNA binding domains and salt-dependent binding mode transitions. *Biochemistry* **1991**, *30*, 2968–2976.

30. Kumar, A.; Wilson, S.H. Studies of the strand-annealing activity of mammalian hnRNP complex protein A1. *Biochemistry* **1990**, *29*, 10717–10722.

31. Mayeda, A.; Munroe, S.H.; Cáceres, J.F.; Krainer, A.R. Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. *EMBO J.* **1994**, *13*, 5483–5495.

32. Cartegni, L.; Maconi, M.; Morandi, E.; Cobianchi, F.; Riva, S.; Biamonti, G. hnRNP A1 selectively interacts through its gly-rich domain with different RNA-binding proteins. *J. Mol. Biol.* **1996**, *259*, 337–348.

33. Eperon, I.C.; Makarova, O.V.; Mayeda, A.; Munroe, S.H.; Caceres, J.F.; Hayward, D.G.; Krainer, A.R. Selection of alternative 5' splice sites: Role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1. *Mol. Cell. Biol.* **2000**, *20*, 8303–8318.

34. Michael, W.M.; Choi, M.; Dreyfuss, G. A nuclear export signal in hnRNP A1: A signal mediated, temperature-dependent nuclear protein export pathway. *Cell* **1995**, *83*, 415–422.

35. Flynn, R.L.; Centore, R.C.; O'Sullivan, R.J.; Rai, R.; Tse, A.; Songyang, Z.; Chang, S.; Karlseder, J.; Zou, L. TERRA and hnRNP A1 orchestrate an RPA-to-POT1 switch on telomeric single-stranded DNA. *Nature* **2011**, *471*, 532–536.

36. Siomi, H.; Dreyfuss, G. A nuclear localization domain in the hnRNP A1 protein. *J. Cell Biol.* **1995**, *129*, 551–560.

37. Pinol-Roma, S.; Dreyfuss, G. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. *Nature* **1992**, *355*, 730–732.
38. Allemand, E.; Guil, S.; Myers, M.; Moscat, J.; Caceres, J.F.; Krainer, A.R. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 3605–3610.

39. Siomi, M.C.; Eder, P.S.; Kataoka, N.; Wan, L.; Liu, Q.; Dreyfuss, G. Transportin-Mediated nuclear import of heterogeneous nuclear RNP proteins. *J. Cell Biol.* **1997**, *138*, 1181–1192.

40. Pollard, V.W.; Michael, W.M.; Nakielny, S.; Siomi, M.C.; Wang, F.; Dreyfuss, G. A novel receptor-mediated nuclear protein import pathway. *Cell* **1996**, *86*, 985–994.

41. Rebane, A.; Aab, A.; Steitz, J.A. Transportins 1 and 2 are redundant nuclear import factors for hnRNP A1 and HuR. *RNA (N. Y.)* **2004**, *10*, 590–599.

42. Herrick, G.; Alberts, B. Purification and physical characterization of nucleic acid helix-unwinding proteins from calf thymus. *J. Biol. Chem.* **1976**, *251*, 2124–2132.

43. Chen, H.; Hewison, M.; Hu, B.; Adams, J.S. Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: A cause of vitamin D resistance. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 6109–6114.

44. Pontius, B.W.; Berg, P. Rapid assembly and disassembly of complementary DNA strands through an equilibrium intermediate state mediated by A1 hnRNP protein. *J. Biol. Chem.* **1992**, *267*, 13815–13818.

45. Kim, S.; Merrill, B.M.; Rajpurohit, R.; Kumar, A.; Stone, K.L.; Papov, V.V.; Schneiders, J.M.; Szer, W.; Wilson, S.H.; Paik, W.K.; *et al.* Identification of N(G)-methylarginine residues in human heterogeneous RNP protein A1: Phe/Gly-Gly-Gly-Arg-Gly-Gly-Gly/Phe is a preferred recognition motif. *Biochemistry* **1997**, *36*, 5185–5192.

46. Burd, C.G.; Dreyfuss, G. RNA binding specificity of hnRNP A1: Significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. *EMBO J.* **1994**, *13*, 1197–1204.

47. Hamilton, B.J.; Nagy, E.; Malter, J.S.; Arrick, B.A.; Rigby, W.F. Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences. *J. Biol. Chem.* **1993**, *268*, 8881–8887.

48. Zhu, J.; Mayeda, A.; Krainer, A.R. Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. *Mol. Cell* **2001**, *8*, 1351–1361.

49. Caputi, M.; Mayeda, A.; Krainer, A.R.; Zahler, A.M. hnRNP A/B proteins are required for inhibition of HIV-1 pre-mRNA splicing. *EMBO J.* **1999**, *18*, 4060–4067.

50. Li, H.P.; Zhang, X.; Duncan, R.; Comai, L.; Lai, M.M. Heterogeneous nuclear ribonucleoprotein A1 binds to the transcription-regulatory region of mouse hepatitis virus RNA. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 9544–9549.

51. Marchand, V.; Mereau, A.; Jacquenet, S.; Thomas, D.; Mougin, A.; Gattoni, R.; Stevenin, J.; Branlant, C. A Janus splicing regulatory element modulates HIV-1 tat and rev mRNA production by coordination of hnRNP A1 cooperative binding. *J. Mol. Biol.* **2002**, *323*, 629–652.

52. Del Gatto, F.; Breathnach, R. Exon and intron sequences, respectively, repress and activate splicing of a *fibroblast growth factor receptor 2* alternative exon. *Mol. Cell. Biol.* **1995**, *15*, 4825–4834.
53. Rajpurohit, R.; Paik, W.K.; Kim, S. Effect of enzymic methylation of heterogeneous ribonucleoprotein particle A1 on its nucleic-acid binding and controlled proteolysis. *Biochem. J.* 1994, 304, 903–909.

54. Shen, E.C.; Henry, M.F.; Weiss, V.H.; Valentini, S.R.; Silver, P.A.; Lee, M.S. Arginine methylation facilitates the nuclear export of hnRNP proteins. *Genes Dev.* 1998, 12, 679–691.

55. Municio, M.M.; Lozano, J.; Sanchez, P.; Moscat, J.; Diaz-Meco, M.T. Identification of heterogeneous ribonucleoprotein A1 as a novel substrate for protein kinase C zeta. *J. Biol. Chem.* 1995, 270, 15884–15891.

56. Idriss, H.; Kumar, A.; Casas-Finet, J.R.; Guo, H.; Damuni, Z.; Wilson, S.H. Regulation of *in vitro* nucleic acid strand annealing activity of heterogeneous nuclear ribonucleoprotein protein A1 by reversible phosphorylation. *Biochemistry* 1994, 33, 11382–11390.

57. Buxade, M.; Parra, J.L.; Rousseau, S.; Shpiro, N.; Marquez, R.; Morrice, N.; Bain, J.; Espel, E.; Proud, C.G. The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. *Immunity* 2005, 23, 177–189.

58. Rigbolt, K.T.; Prokhorova, T.A.; Akimov, V.; Henningsen, J.; Johansen, P.T.; Krachtmarova, I.; Kassem, M.; Mann, M.; Olsen, J.V.; Blagoev, B. System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. *Sci. Signal.* 2011, 4, doi:10.1126/scisignal.2001570.

59. Dephoure, N.; Zhou, C.; Villen, J.; Beausoleil, S.A.; Bakalarski, C.E.; Elledge, S.J.; Gygi, S.P. A quantitative atlas of mitotic phosphorylation. *Proc. Natl. Acad. Sci. USA* 2008, 105, 10762–10767.

60. Li, T.; Evdokimov, E.; Shen, R.F.; Chao, C.C.; Tekle, E.; Wang, T.; Stadman, E.R.; Yang, D.C.; Chock, P.B. Sumoylation of heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore complex proteins: A proteomic analysis. *Proc. Natl. Acad. Sci. USA* 2004, 101, 8551–8556.

61. Lau, J.S.; Baumeister, P.; Kim, E.; Roy, B.; Hsieh, T.Y.; Lai, M.; Lee, A.S. Heterogeneous nuclear ribonucleoproteins as regulators of gene expression through interactions with the human thymidine kinase promoter. *J. Cell. Biochem.* 2000, 79, 395–406.

62. Xia, H. Regulation of gamma-fibrinogen chain expression by heterogeneous nuclear ribonucleoprotein A1. *J. Biol. Chem.* 2005, 280, 13171–13178.

63. Campillos, M.; Lamas, J.R.; Garcia, M.A.; Bullido, M.J.; Valdivieso, F.; Vazquez, J. Specific interaction of heterogeneous nuclear ribonucleoprotein A1 with the -219T allelic form modulates *APOE* promoter activity. *Nucleic Acids Res.* 2003, 31, 3063–3070.

64. Das, S.; Ward, S.V.; Markle, D.; Samuel, C.E. DNA damage-binding proteins and heterogeneous nuclear ribonucleoprotein A1 function as constitutive KCS element components of the interferon-inducible RNA-dependent protein kinase promoter. *J. Biol. Chem.* 2004, 279, 7313–7321.

65. Fukuda, H.; Katahira, M.; Tsuchiya, N.; Enokizono, Y.; Sugimura, T.; Nagao, M.; Nakagama, H. Unfolding of quadruplex structure in the G-rich strand of the minisatellite repeat by the binding protein UP1. *Proc. Natl. Acad. Sci. USA* 2002, 99, 12685–12690.

66. Kan, Z.Y.; Lin, Y.; Wang, F.; Zhuang, X.Y.; Zhao, Y.; Pang, D.W.; Hao, Y.H.; Tan, Z. G-quadruplex formation in human telomeric (TTAGGG)4 sequence with complementary strand in close vicinity under molecularly crowded condition. *Nucleic Acids Res.* 2007, 35, 3646–3653.
67. Paramasivam, M.; Membrino, A.; Cogoi, S.; Fukuda, H.; Nakagama, H.; Xodo, L.E. Protein hnRNP A1 and its derivative Up1 unfold quadruplex DNA in the human KRAS promoter: Implications for transcription. *Nucleic Acids Res.* **2009**, *37*, 2841–2853.

68. Takimoto, M.; Tomonaga, T.; Matunis, M.; Avigan, M.; Krutzsch, H.; Dreyfuss, G.; Levens, D. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, *in vitro.* *J. Biol. Chem.* **1993**, *268*, 18249–18258.

69. Diribarne, G.; Bensaude, O. 7SK RNA, a non-coding RNA regulating P-TEFb, a general transcription factor. *RNA Biol.* **2009**, *6*, 122–128.

70. Barrandon, C.; Bonnet, F.; Nguyen, V.T.; Labas, V.; Bensaude, O. The transcription-dependent dissociation of P-TEFb-HEXIM1–7SK RNA relies upon formation of hnRNP-7SK RNA complexes. *Mol. Cell. Biol.* **2007**, *27*, 6996–7006.

71. Van Herreweghe, E.; Egloff, S.; Goiffon, I.; Jady, B.E.; Froment, C.; Monsarrat, B.; Kiss, T. Dynamic remodelling of human 7SK snRNP controls the nuclear level of active P-TEFb. *EMBO J.* **2007**, *26*, 3570–3580.

72. Hay, D.C.; Kemp, G.D.; Dargemont, C.; Hay, R.T. Interaction between hnRNP A1 and IkappaBalpha is required for maximal activation of NF-kappaB-dependent transcription. *Mol. Cell. Biol.* **2001**, *21*, 3482–3490.

73. Moore, M.J.; Query, C.C.; Sharp, P.A. Splicing of Precursors to mRNA by the Spliceosome. In *The RNA World*; Gesteland, R.F., Atkins, J.F., Eds.; Cold Spring Harbor Press: New York, NY, USA, 1993; pp. 303–357.

74. Nilsen, T.W. RNA-RNA interactions in the spliceosome: Unraveling the ties that bind. *Cell* **1994**, *78*, 1–4.

75. Black, D.L. Finding splice sites within a wilderness of RNA. *RNA (N. Y.)* **1995**, *1*, 763–771.

76. Jurica, M.S.; Licklider, L.J.; Gygi, S.R.; Grigorieff, N.; Moore, M.J. Purification and characterization of native spliceosomes suitable for three-dimensional structural analysis. *RNA (N. Y.)* **2002**, *8*, 426–439.

77. Black, D.L. Mechanisms of alternative pre-messenger RNA splicing. *Ann. Rev. Biochem.* **2003**, *72*, 291–336.

78. Smith, C.W.J.; Valcarcel, J. Alternative pre-mRNA splicing: The logic of combinatorial control. *TIBS* **2000**, *25*, 381–388.

79. Johnson, J.M.; Castle, J.; Garrett-Engele, P.; Kan, Z.; Loerch, P.M.; Armour, C.D.; Santos, R.; Schadt, E.E.; Stoughton, R.; Shoemaker, D.D. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. *Science (N. Y.)* **2003**, *302*, 2141–2144.

80. Blencowe, B.J. Alternative splicing: new insights from global analyses. *Cell* **2006**, *126*, 37–47.

81. Wang, E.T.; Sandberg, R.; Luo, S.; Khrebtukova, I.; Zhang, L.; Mayr, C.; Kingsmore, S.F.; Schroth, G.P.; Burge, C.B. Alternative isoform regulation in human tissue transcriptomes. *Nature* **2008**, *456*, 470–476.

82. Krecic, A.M.; Swanson, M.S. hnRNP complexes: Composition, structure, and function. *Curr. Opin. Cell Biol.* **1999**, *11*, 363–371.

83. Graveley, B.R. Sorting out the complexity of SR protein functions. *RNA (N. Y.)* **2000**, *6*, 1197–1211.
84. Caceres, J.F.; Stamm, S.; Helfman, D.M.; Krainer, A.R. Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science (N. Y.) 1994, 265, 1706–1709.
85. Zhou, Z.; Licklider, L.J.; Gygi, S.P.; Reed, R. Comprehensive proteomic analysis of the human spliceosome. Nature 2002, 419, 182–185.
86. Tavanez, J.P.; Madl, T.; Kooshapur, H.; Sattler, M.; Valcarcel, J. hnRNP A1 proofreads 3' splice site recognition by U2AF. Mol. Cell 2012, 45, 314–329.
87. Mayeda, A.; Krainer, A.R. Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell 1992, 68, 365–375.
88. Venables, J.P.; Bourgeois, C.F.; Dalgliesh, C.; Kister, L.; Stevenin, J.; Elliott, D.J. Up-Regulation of the ubiquitous alternative splicing factor Tra2beta causes inclusion of a germ cell-specific exon. Hum. Mol. Genet. 2003, 14, 2289–2303.
89. Dirksen, W.P.; Li, X.; Mayeda, A.; Krainer, A.R.; Rottman, F.M. Mapping the SF2/ASF binding sites in the bovine growth hormone exonic splicing enhancer. J. Biol. Chem. 2000, 275, 29170–29177.
90. Sun, Q.; Hampson, R.K.; Rottman, F.M. In vitro analysis of bovine growth hormone pre-messenger RNA alternative splicing-involvement of exon sequences and trans-acting factor(s). J. Biol. Chem. 1993, 268, 15659–15666.
91. Rooke, N.; Markovtsov, V.; Cagavi, E.; Black, D.L. Roles for SR proteins and hnRNP A1 in the regulation of c-src exon N1. Mol. Cell. Biol. 2003, 23, 1874–1884.
92. Kashima, T.; Manley, J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 2003, 34, 460–463.
93. Cartegni, L.; Krainer, A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 2002, 30, 377–384.
94. Okunola, H.L.; Krainer, A.R. Cooperative-Binding and splicing-repressive properties of hnRNP A1. Mol. Cell. Biol. 2009, 29, 5620–5631.
95. Guo, R.; Li, Y.; Ning, J.; Sun, D.; Lin, L.; Liu, X. HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor-3 and affect immunomodulatory functions in human non-small cell lung cancer cells. PLoS One 2013, 8, e62729.
96. Tange, T.O.; Damgaard, C.K.; Guth, S.; Valcarcel, J.; Kjems, J. The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element. EMBO J. 2001, 20, 5748–5758.
97. Blanchette, M.; Chabot, B. Modulation of exon skipping by high-affinity hnRNP A1-binding sites and by intron elements that repress splice site utilization. EMBO J. 1999, 18, 1939–1952.
98. Nasim, F.U.; Hutchison, S.; Cordeau, M.; Chabot, B. High-affinity hnRNP A1 binding sites and duplex-forming inverted repeats have similar effects on 5' splice site selection in support of a common looping out and repression mechanism. RNA (N. Y.) 2002, 8, 1078–1089.
99. Bruun, G.H.; Doktor, T.K.; Andresen, B.S. A synonymous polymorphic variation in ACADM exon 11 affects splicing efficiency and may affect fatty acid oxidation. Mol. Genet. Metab. 2013, 110, 122–128.
100. Zearfoss, N.R.; Johnson, E.S.; Ryder, S.P. hnRNP A1 and secondary structure coordinate alternative splicing of Mag. RNA (N. Y.) 2013, 19, 948–957.
101. Oh, H.; Lee, E.; Jang, H.N.; Lee, J.; Moon, H.; Sheng, Z.; Jun, Y.; Loh, T.J.; Cho, S.; Zhou, J.; et al. hnRNP A1 contacts exon 5 to promote exon 6 inclusion of apoptotic Fas gene. *Apoptosis* 2013, 18, 825–835.

102. Pelisch, F.; Khauv, D.; Risso, G.; Stallings-Mann, M.; Blaustein, M.; Quadrana, L.; Radisky, D.C.; Srebrow, A. Involvement of hnRNP A1 in the matrix metalloprotease-3-dependent regulation of *Rac1* pre-mRNA splicing. *J. Cell. Biochem.* 2013, 113, 2319–2329.

103. Talukdar, I.; Sen, S.; Urbano, R.; Thompson, J.; Yates, J.R., III; Webster, N.J. hnRNP A1 and hnRNP F modulate the alternative splicing of exon 11 of the *insulin receptor* gene. *PLoS One* 2013, 6, e27869.

104. Goina, E.; Skoko, N.; Pagani, F. Binding of DAZAP1 and hnRNP A1/A2 to an exonic splicing silencer in a natural *BRCA1* exon 18 mutant. *Mol. Cell. Biol.* 2008, 28, 3850–3860.

105. Raponi, M.; Kralovicova, J.; Copson, E.; Divina, P.; Eccles, D.; Johnson, P.; Baralle, D.; Vorechovsky, I. Prediction of single-nucleotide substitutions that result in exon skipping: Identification of a splicing silencer in *BRCA1* exon 6. *Hum. Mutat.* 2011, 32, 436–444.

106. Dirksen, W.P.; Sun, Q.; Rottman, F.M. Multiple splicing signals control alternative intron retention of bovine growth hormone pre-mRNA. *J. Biol. Chem.* 1995, 270, 5346–5352.

107. Doktor, T.K.; Schroeder, L.D.; Vested, A.; Palmfeldt, J.; Andersen, H.S.; Gregersen, N.; Andresen, B.S. *SMN2* exon 7 splicing is inhibited by binding of hnRNP A1 to a common ESS motif that spans the 3’ splice site. *Hum. Mutat.* 2011, 32, 220–230.

108. Kashima, T.R.N.; David, C.J.; Manley, J.L. hnRNP A1 functions with specificity in repression of *SMN2* exon 7 splicing. *Hum. Mol. Genet.* 2007, 16, 3149–3159.

109. Singh, N.N.; Androphy, E.J.; Singh, R.N. An extended inhibitory context causes skipping of exon 7 of *SMN2* in spinal muscular atrophy. *Biochem. Biophys. Res. Commun.* 2004, 315, 381–388.

110. Kashima, T.; Rao, N.; Manley, J.L. An intronic element contributes to splicing repression in spinal muscular atrophy. *Proc. Natl. Acad. Sci. USA* 2007, 104, 3426–3431.

111. DelGatto-Konczak, F.; Olive, M.; Gesnel, M.C.; Breathnach, R. hnRNPA1 recruited to an exon *in vivo* can function as an exon splicing silencer. *Mol. Cell. Biol.* 1999, 19, 251–260.

112. Gesnel, M.C.; del Gatto-Konczak, F.; Breathnach, R. Combined use of MS2 and PP7 coat fusions shows that TIA-1 dominates hnRNP A1 for K-SAM exon splicing control. *J. Biomed. Biotechnol.* 2009, 2009, 104853.

113. Donev, R.; Newall, A.; Thome, J.; Sheer, D. A role for SC35 and hnRNP A1 in the determination of amyloid precursor protein isoforms. *Mol. Psychiatr.* 2007, 12, 681–690.

114. Disset, A.; Bourgeois, C.F.; Benmalek, N.; Claustres, M.; Stevenin, J.; Tuffery-Giraud, S. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements. *Hum. Mol. Genet.* 2006, 15, 999–1013.

115. Expert-Bezancon, A.; Sureau, A.; Durosay, P.; Salesse, R.; Groeneveld, H.; Lecaer, J.P.; Marie, J. hnRNP A1 and the SR proteins ASF/SF2 and SC35 have antagonistic functions in splicing of *beta-tropomyosin* exon 6B. *J. Biol. Chem.* 2004, 279, 38249–38259.
116. Princeler, G.L.; Julias, J.G.; Hughes, S.H.; Derse, D. Roles of viral and cellular proteins in the expression of alternatively spliced HTLV-1 pX mRNAs. *Virology* 2003, 317, 136–145.

117. Guil, S.; Gattoni, R.; Carrascal, M.; Abian, J.; Stevenin, J.; Bach-Elias, M. Roles of hnRNP A1, SR proteins, and p68 helicase in *c-H-ras* alternative splicing regulation. *Mol. Cell. Biol.* 2003, 23, 2927–2941.

118. Damgaard, C.K.; Tange, T.O.; Kjems, J. hnRNP A1 controls HIV-1 mRNA splicing through cooperative binding to intron and exon splicing silencers in the context of a conserved secondary structure. *RNA (N. Y.)* 2002, 8, 1401–1415.

119. Dery, K.J.; Gaur, S.; Gencheva, M.; Yen, Y.; Shively, J.E.; Gaur, R.K. Mechanistic control of *carcinoembryonic antigen-related cell adhesion molecule-1* (*CEACAM1*) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M. *J. Biol. Chem.* 2011, 286, 16039–16051.

120. David, C.J.; Chen, M.; Assanah, M.; Canoll, P.; Manley, J.L. HnRNP proteins controlled by c-Myc deregulate *pyruvate kinase* mRNA splicing in cancer. *Nature* 2010, 463, 364–368.

121. Bilodeau, P.S.; Domsic, J.K.; Mayeda, A.; Krainer, A.R.; Stoltzfus, C.M. RNA splicing at human immunodeficiency virus type 1 3' splice site A2 is regulated by binding of hnRNP A/B proteins to an exonic splicing silencer element. *J. Virol.* 2001, 75, 8487–8497.

122. Rosenberger, S.; De-Castro Arce, J.; Langbein, L.; Steenbergen, R.D.; Rosl, F. Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. *Proc. Natl. Acad. Sci. USA* 2010, 107, 7006–7011.

123. Pastor, T.; Pagani, F. Interaction of hnRNP A1/A2 and DAZAP1 with an Alu-derived intronic splicing enhancer regulates ATM aberrant splicing. *PLoS One* 2011, 6, e23349.

124. Blackburn, E.H. Switching and signaling at the telomere. *Cell* 2001, 106, 661–673.

125. Parkinson, G.N.; Lee, M.P.; Neidle, S. Crystal structure of parallel quadruplexes from human telomeric DNA. *Nature* 2002, 417, 876–880.

126. Parkinson, G.N.; Lee, M.P.; Neidle, S. Crystal structure of parallel quadruplexes from human telomeric DNA. *Nature* 2002, 417, 876–880.

127. Meeker, A.K.; de Marzo, A.M. Recent advances in telomere biology: Implications for human cancer. *Curr. Opin. Oncol.* 2004, 16, 32–38.

128. Zhang, Q.S.; Manche, L.; Xu, R.M.; Krainer, A.R. hnRNP A1 associates with telomere ends and stimulates telomerase activity. *RNA (N. Y.)* 2006, 12, 1116–1128.

129. LaBranche, H.; Dupuis, S.; Ben-David, Y.; Bani, M.R.; Wellinger, R.J.; Chabot, B. Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. *Nat. Genet.* 1998, 19, 199–202.

130. Fiset, S.; Chabot, B. hnRNP A1 may interact simultaneously with telomeric DNA and the human telomerase RNA in vitro. *Nucleic Acids Res.* 2001, 29, 2268–2275.

131. Lopez de Silanes, I.; Stagnod’Alcontres, M.; Blasco, M.A. TERRA transcripts are bound by a complex array of RNA-binding proteins. *Nat. Commun.* 2010, 1, 33.

132. Le, P.N.; Maranon, D.G.; Altina, N.H.; Battaglia, C.L.; Bailey, S.M. TERRA, hnRNP A1, and DNA-PKcs Interactions at Human Telomeres. *Front. Oncol.* 2013, 3, 91.
133. Dallaire, F.; Dupuis, S.; Fiset, S.; Chabot, B. Heterogeneous nuclear ribonucleoprotein A1 and UP1 protect mammalian telomeric repeats and modulate telomere replication in vitro. J. Biol. Chem. 2000, 275, 14509–14516.

134. Mili, S.; Shu, H.J.; Zhao, Y.; Pinol-Roma, S. Distinct RNP complexes of shuttling hnRNP proteins with pre-mRNA and mRNA: Candidate intermediates in formation and export of mRNA. Mol. Cell. Biol. 2001, 21, 7307–7319.

135. Nakielny, S.; Dreyfuss, G. Transport of proteins and RNAs in and out of the nucleus. Cell 1999, 99, 677–690.

136. Izaurrealde, E.; Jarmolowski, A.; Beisel, C.; Mattaj, I.W.; Dreyfuss, G.; Fischer, U. A role for the M9 transport signal of hnRNP A1 in mRNA nuclear export. J. Cell Biol. 1997, 137, 27–35.

137. Gallouzi, I.E.; Steitz, J.A. Delineation of mRNA export pathways by the use of cell-permeable peptides. Science (N. Y.) 2001, 294, 1895–1901.

138. Visa, N.; Alzhanova-Ericsson, A.T.; Sun, X.; Kiseleva, E.; Bjorkroth, B.; Wurtz, T.; Daneholt, B. A pre-mRNA-binding protein accompanies the RNA from the gene through the nuclear pores and into polysomes. Cell 1996, 84, 253–264.

139. Siebrasse, J.P.; Kaminski, T.; Kubitscheck, U. Nuclear export of single native mRNA molecules observed by light sheet fluorescence microscopy. Proc. Natl. Acad. Sci. USA 2012, 109, 9426–9431.

140. Vautier, D.; Chesne, P.; Cunha, C.; Calado, A.; Renard, J.P.; Carmo-Fonseca, M. Transcription-Dependent nucleocytoplasmic distribution of hnRNP A1 protein in early mouse embryos. J. Cell Sci. 2001, 114, 1521–1531.

141. Kataoka, N.; Yong, J.; Kim, V.N.; Velazquez, F.; Perkinson, R.A.; Wang, F.; Dreyfuss, G. Pre-mRNA splicing imprints mRNA in the nucleus with a novel RNA-binding protein that persists in the cytoplasm. Mol. Cell 2000, 6, 673–682.

142. Barreau, C.; Paillard, L.; Osborne, H.B. AU-Rich elements and associated factors: Are there unifying principles? Nucleic Acids Res. 2005, 33, 7138–7150.

143. Henics, T.; Sanfridson, A.; Hamilton, B.J.; Nagy, E.; Rigby, W.F. Enhanced stability of interleukin-2 mRNA in MLA 144 cells. Possible role of cytoplasmic AU-rich sequence-binding proteins. J. Biol. Chem. 1994, 269, 5377–5383.

144. Hamilton, B.J.; Burns, C.M.; Nichols, R.C.; Rigby, W.F. Modulation of AUUUA response element binding by heterogeneous nuclear ribonucleoprotein A1 in human T lymphocytes. The roles of cytoplasmic location, transcription, and phosphorylation. J. Biol. Chem. 1997, 272, 28732–28741.

145. Svitkin, Y.V.; Ovchinnikov, L.P.; Dreyfuss, G.; Sonenberg, N. General RNA binding proteins render translation cap dependent. EMBO J. 1996, 15, 7147–7155.

146. Martinez-Salas, E.; Pineiro, D.; Fernandez, N. Alternative mechanisms to initiate translation in eukaryotic mRNAs. Comp. Funct. Gen. 2012, 2012, 391546.

147. Bonnal, S.; Pileur, F.; Orsini, C.; Parker, F.; Pujol, F.; Prats, A.C.; Vagner, S. Heterogeneous nuclear ribonucleoprotein A1 is a novel internal ribosome entry site trans-acting factor that modulates alternative initiation of translation of the fibroblast growth factor 2 mRNA. J. Biol. Chem. 2005, 280, 4144–4153.
148. Cammas, A.; Pileur, F.; Bonnal, S.; Lewis, S.M.; Leveque, N.; Holcik, M.; Vagner, S. Cytoplasmic relocalization of heterogeneous nuclear ribonucleoprotein A1 controls translation initiation of specific mRNAs. Mol. Biol. Cell 2007, 18, 5048–5059.

149. Damiano, F.; Rochira, A.; Tocci, R.; Alemanno, S.; Gnoni, A.; Siculella, L. hnRNP A1 mediates the activation of the IRES-dependent SREBP-1a mRNA translation in response to endoplasmic reticulum stress. Biochem. J. 2013, 449, 543–553.

150. Jo, O.D.; Martin, J.; Bernath, A.; Masri, J.; Lichtenstein, A.; Gera, J. Heterogeneous nuclear ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through Akt signaling. J. Biol. Chem. 2008, 283, 23274–23287.

151. Martin, J.; Masri, J.; Cloninger, C.; Holmes, B.; Artinian, N.; Funk, A.; Ruegg, T.; Anderson, L.; Bashir, T.; Bernath, A.; et al. Phosphomimetic substitution of heterogeneous nuclear ribonucleoprotein A1 at serine 199 abolishes AKT-dependent internal ribosome entry site-transacting factor (ITAF) function via effects on strand annealing and results in mammalian target of rapamycin complex 1 (mTORC1) inhibitor sensitivity. J. Biol. Chem. 2011, 286, 16402–16413.

152. Lewis, S.M.; Veyrier, A.; Hosszu Ungureanu, N.; Bonnal, S.; Vagner, S.; Holcik, M. Subcellular relocalization of a trans-acting factor regulates XIAP IRES-dependent translation. Mol. Biol. Cell 2007, 18, 1302–1311.

153. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233.

154. Kim, V.N.; Han, J.; Siomi, M.C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 2009, 10, 126–139.

155. Guil, S.; Caceres, J.F. The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat. Struct. Mol. Biol. 2007, 14, 591–596.

156. Michlewski, G.; Guil, S.; Semple, C.A.; Caceres, J.F. Posttranscriptional regulation of miRNAs harboring conserved terminal loops. Mol. Cell 2008, 32, 383–393.

157. Roush, S.; Slack, F.J. The let-7 family of microRNAs. Trends Cell Biol. 2008, 18, 505–516.

158. Michlewski, G.; Caceres, J.F. Antagonistic role of hnRNP A1 and KSRP in the regulation of let-7a biogenesis. Nat. Struct. Mol. Biol. 2010, 17, 1011–1018.

159. Gherzi, R.; Chen, C.Y.; Trabucchi, M.; Ramos, A.; Briata, P. The role of KSRP in mRNA decay and microRNA precursor maturation. Wiley Interdiscip. Rev. 2010, 1, 230–239.

160. Pino, I.; Pio, R.; Toledo, G.; Zabalegui, N.; Vicent, S.; Rey, N.; Lozano, M.D.; Torre, W.; Garcia-Foncillas, J.; Montuenga, L.M. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer (Amsterdam, The Netherlands) 2003, 41, 131–143.

161. Ushigome, M.; Ubagai, T.; Fukuda, H.; Tsuchiya, N.; Sugimura, T.; Takatsuka, J.; Nakagama, H. Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers. Int. J. Oncol. 2005, 26, 635–640.

162. Carpenter, B.; MacKay, C.; Alnabulsi, A.; MacKay, M.; Telfer, C.; Melvin, W.T.; Murray, G.I. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim. Biophys. Acta 2006, 1765, 85–100.
163. Boukakis, G.; Patrinou-Georgoula, M.; Lekarakou, M.; Valavanis, C.; Guialis, A. Deregulated expression of hnRNP A/B proteins in human non-small cell lung cancer: Parallel assessment of protein and mRNA levels in paired tumour/non-tumour tissues. *BMC Cancer* 2010, 10, 434.

164. Venables, J.P. Unbalanced alternative splicing and its significance in cancer. *Bioessays* 2006, 28, 378–386.

165. Venables, J.P.; Koh, C.S.; Froehlich, U.; Lapointe, E.; Couture, S.; Inkel, L.; Bramard, A.; Paquet, E.R.; Watier, V.; Durand, M.; *et al.* Multiple and specific mRNA processing targets for the major human hnRNP proteins. *Mol. Cell. Biol.* 2008, 28, 6033–6043.

166. Zhou, Z.J.; Dai, Z.; Zhou, S.L.; Fu, X.T.; Zhao, Y.M.; Shi, Y.H.; Zhou, J.; Fan, J. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma. *Int. J. Cancer* 2012, 132, 1080–1089.

167. Patry, C.; Bouchard, L.; Labrecque, P.; Gendron, D.; Lemieux, B.; Toutant, J.; Lapointe, E.; Wellinger, R.; Chabot, B. Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticle A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. *Cancer Res.* 2003, 63, 7679–7688.

168. Jiang, Z.H.; Zhang, W.J.; Rao, Y.; Wu, J.Y. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. *Proc. Natl. Acad. Sci. USA* 1998, 95, 9155–9160.

169. Bekenstein, U.; Soreq, H. Heterogeneous nuclear ribonucleoprotein A1 in health and neurodegenerative disease: From structural insights to post-transcriptional regulatory roles. *Mol. Cell. Neurosci.* 2012, doi:10.1016/j.mcn.2012.12.002.

170. Berson, A.; Barbash, S.; Shaltiel, G.; Goll, Y.; Hanin, G.; Greenberg, D.S.; Ketzef, M.; Becker, A.J.; Friedman, A.; Soreq, H. Cholinergic-associated loss of hnRNP-A/B in Alzheimer’s disease impairs cortical splicing and cognitive function in mice. *EMBO Mol. Med.* 2012, 4, 730–742.

171. Kim, H.J.; Kim, N.C.; Wang, Y.D.; Scarborough, E.A.; Moore, J.; Diaz, Z.; MacLea, K.S.; Freibaum, B.; Li, S.; Molliex, A.; *et al.* Mutations in prion-like domains in *hnRNPA2B1* and *hnRNP A1* cause multisystem proteinopathy and ALS. *Nature* 2013, 495, 467–473.

172. Shih, S.R.; Stollar, V.; Li, M.L. Host factors in enterovirus 71 replication. *J. Virol.* 2011, 85, 9658–9666.

173. Lin, J.Y.; Shih, S.R.; Pan, M.; Li, C.; Lue, C.F.; Stollar, V.; Li, M.L. hnRNP A1 interacts with the 5' untranslated regions of enterovirus 71 and Sindbis virus RNA and is required for viral replication. *J. Virol.* 2009, 83, 6106–6114.

174. Kim, C.S.; Seol, S.K.; Song, O.K.; Park, J.H.; Jang, S.K. An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6, facilitate hepatitis C virus replication. *J. Virol.* 2007, 81, 3852–3865.

175. Zhao, X.; Schwartz, S. Inhibition of HPV-16 L1 expression from L1 cDNAs correlates with the presence of hnRNP A1 binding sites in the L1 coding region. *Virus Genes* 2008, 36, 45–53.

176. Zhao, X.; Fay, J.; Lambkin, H.; Schwartz, S. Identification of a 17-nucleotide splicing enhancer in HPV-16 *L1* that counteracts the effect of multiple hnRNP A1-binding splicing silencers. *Virology* 2007, 369, 351–363.
177. Karn, J.; Stoltzfus, C.M. Transcriptional and posttranscriptional regulation of HIV-1 gene expression. *Cold Spring Harbor Perspect. Med.* 2012, 2, a006916.

178. Jablonski, J.A.; Caputi, M. Role of cellular RNA processing factors in human immunodeficiency virus type 1 mRNA metabolism, replication, and infectivity. *J. Virol.* 2009, 83, 981–992.

179. Monette, A.; Ajamian, L.; Lopez-Lastra, M.; Mouland, A.J. Human immunodeficiency virus type 1 (HIV-1) induces the cytoplasmic retention of heterogeneous nuclear ribonucleoprotein A1 by disrupting nuclear import: Implications for HIV-1 gene expression. *J. Biol. Chem.* 2009, 284, 31350–31362.

180. Najera, I.; Krieg, M.; Karn, J. Synergistic stimulation of HIV-1 Rev-dependent export of unspliced mRNA to the cytoplasm by hnRNP A1. *J. Mol. Biol.* 1999, 285, 1951–1964.

181. Lorson, C.L.; Rindt, H.; Shababi, M. Spinal muscular atrophy: Mechanisms and therapeutic strategies. *Hum. Mol. Genet.* 2010, 19, R111–R118.

182. Mitropant, C.; Porensky, P.; Zhou, H.; Price, L.; Muntoni, F.; Fletcher, S.; Wilton, S.D.; Burghes, A.H. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: Towards a treatment for spinal muscular atrophy. *PLoS One* 2013, 8, e62114.

183. Rigo, F.; Hua, Y.; Krainer, A.R.; Bennett, C.F. Antisense-Based therapy for the treatment of spinal muscular atrophy. *J. Cell Biol.* 2012, 199, 21–25.

184. Hua, Y.; Sahashi, K.; Hung, G.; Rigo, F.; Passini, M.A.; Bennett, C.F.; Krainer, A.R. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. *Genes Dev.* 2010, 24, 1634–1644.

185. Hua, Y.; Vickers, T.A.; Okunola, H.L.; Bennett, C.F.; Krainer, A.R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. *Am. J. Hum. Genet.* 2008, 82, 834–848.

186. Li, S.; Wang, W.; Ding, H.; Xu, H.; Zhao, Q.; Li, J.; Li, H.; Xia, W.; Su, X.; Chen, Y.; et al. Aptamer BC15 against heterogeneous nuclear ribonucleoprotein A1 has potential value in diagnosis and therapy of hepatocarcinoma. *Nucleic Acid Ther.* 2012, 22, 391–398.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).